Protagonist Therapeutics Inc Cash Flow-to-Debt Ratio
Protagonist Therapeutics Inc cash flow-to-debt ratio. Protagonist Therapeutics Inc (PTGX) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of $-1.94 Million could theoretically repay 0% of its total liabilities ($56.25 Million) in one year. Check Protagonist Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Protagonist Therapeutics Inc (2014–2024)
Cash flow-to-debt ratio of Protagonist Therapeutics Inc from 2014 to 2024. Historical debt coverage capacity for Protagonist Therapeutics Inc across 11 annual periods. Check Protagonist Therapeutics Inc (PTGX) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Protagonist Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2014–2024)
Protagonist Therapeutics Inc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Protagonist Therapeutics Inc. For the full cash flow conversion analysis, see PTGX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 2.65x | $184.15 Million | $69.43 Million | ▲ +180.3% |
| 2023 | -3.30x | $-70.24 Million | $21.27 Million | ▲ +1.3% |
| 2022 | -3.35x | $-108.14 Million | $32.32 Million | ▼ -47.9% |
| 2021 | -2.26x | $-107.86 Million | $47.67 Million | ▼ -40.0% |
| 2020 | -1.62x | $-72.48 Million | $44.86 Million | ▼ -191.6% |
| 2019 | -0.55x | $-41.53 Million | $74.95 Million | ▲ +70.1% |
| 2018 | -1.85x | $-49.95 Million | $26.96 Million | ▼ -2162.5% |
| 2017 | 0.09x | $3.87 Million | $43.10 Million | ▲ +101.9% |
| 2016 | -4.66x | $-29.97 Million | $6.43 Million | ▼ -70.0% |
| 2015 | -2.74x | $-14.38 Million | $5.25 Million | ▲ +16.0% |
| 2014 | -3.26x | $-7.74 Million | $2.37 Million | — |